4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
US-9259426-B2 · Feb 16, 2016 · US
Toll like receptor modulator compounds
US10285990B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10285990-B2 |
| Application number | US-201715496283-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 25, 2017 |
| Priority date | Mar 4, 2015 |
| Publication date | May 14, 2019 |
| Grant date | May 14, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure relates generally to toll like receptor modulator compounds, such as diamino pyrido[3,2 D] pyrimidine compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR-8), and methods of making and using them.
First claim
Opening claim text (preview).
We claim: 1. A method of treating a hepatitis B viral infection, comprising administering to an individual in need thereof a therapeutically effective amount of a compound which is or a pharmaceutically acceptable salt thereof. 2. The method of claim 1 , further comprising administering one or more additional therapeutic agents. 3. The method of claim 1 , further comprising administering tenofovir alafenamide, tenofovir alafenamide fumarate, or tenofovir alafenamide hemifumarate. 4. A method of treating a hepatitis B viral infection, comprising administering to an individual in need thereof a therapeutically effective amount of a compound which is 5. The method of claim 4 , further comprising administering one or more additional therapeutic agents. 6. The method of claim 4 , further comprising administering tenofovir alafenamide, tenofovir alafenamide fumarate, or tenofovir alafenamide hemifumarate.
Assignees
Inventors
Classifications
directly linked by a ring-member-to-ring-member bond · CPC title
Nitrogen atoms · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Drugs for immunological or allergic disorders · CPC title
specific for metastasis · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10285990B2 cover?
- The present disclosure relates generally to toll like receptor modulator compounds, such as diamino pyrido[3,2 D] pyrimidine compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR-8), and methods of making and using them.
- Who is the assignee on this patent?
- Gilead Sciences Inc
- What technology area does this patent fall under?
- Primary CPC classification A61P31/18. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue May 14 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).